Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 3 5 M IN PLASTIC CONTAINER versus AMINOSYN II 7 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 3 5 M IN PLASTIC CONTAINER versus AMINOSYN II 7 W ELECTROLYTES.
AMINOSYN II 3.5% M IN PLASTIC CONTAINER vs AMINOSYN II 7% W/ ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 3.5% M is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis and nitrogen balance maintenance in patients unable to tolerate oral/enteral nutrition. The 'M' formulation includes electrolytes and trace elements. Amino acids are incorporated into endogenous proteins, serving as substrates for gluconeogenesis, oxidative metabolism, and neurotransmitter synthesis.
Provides essential and non-essential amino acids for protein synthesis, promotes nitrogen balance, and serves as a caloric source in parenteral nutrition.
Intravenous administration; typical adult dose is 1 to 2 g amino acids/kg/day, corresponding to 30 to 60 mL/kg/day of 3.5% solution; infusion rate not to exceed 0.1 g amino acids/kg/hour.
Adults: 500 mL to 2000 mL/day intravenously via central line at a rate not exceeding 100 mL/hour. Dosage based on protein requirement (0.8-1.5 g/kg/day) and nutritional status.
None Documented
None Documented
Variable; amino acids have short plasma half-lives (minutes to hours) due to rapid cellular uptake and metabolism; no meaningful terminal half-life for the mixture.
Variable; amino acids: 10–40 minutes (rapid distribution and metabolism); clinical context: continuous infusion required to maintain steady state
100% renal; amino acids are deaminated and metabolized to urea, which is excreted renally; minimal (<1%) biliary/fecal excretion.
Renal: >80% as amino acids and metabolites; fecal: negligible; biliary: <5%
Category C
Category C
Amino Acid Solution
Amino Acid Solution